- Home
- SOC vs IRWD Comparison
SOC vs IRWD Comparison
Compare SOC & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOC | IRWD |
|---|---|---|
| Founded | 2020 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.8M | 687.4M |
| IPO Year | 2021 | 2009 |
Fundamental Metrics
Financial Performance| Metric | SOC | IRWD |
|---|---|---|
| Price | $3.62 | $3.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $9.33 | $6.10 |
| AVG Volume (30 Days) | ★ 7.1M | 2.0M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.61 | ★ 1400.00 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $59.19 |
| Revenue Next Year | $82.49 | $4.80 |
| P/E Ratio | ★ N/A | $6.89 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $2.88 | $1.43 |
| 52 Week High | $19.25 | $5.78 |
Technical Indicators
Market Signals| Indicator | SOC | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 38.17 | 35.47 |
| Support Level | $3.28 | $3.04 |
| Resistance Level | $5.38 | $3.96 |
| Average True Range (ATR) | 0.28 | 0.17 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 27.79 | 2.78 |
Price Performance
Historical ComparisonAbout SOC Sable Offshore Corp.
Sable Offshore Corp is a Houston-based independent upstream company focused on developing the Santa Ynez Unit in federal waters offshore California. The company operates as one reportable oil and gas segment and is engaged in the acquisition, development, exploration, and production of oil and natural gas.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.